Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Weight Change in DLBCL

Studying change before and after therapy

Weight management strategies may be an important part of long-term survivorship planning after conclusion of treatment, according to a retrospective cohort study of 1,935 patients with diffuse large B-cell lymphoma (DLBCL) who received cyclophosphamide, doxorubicin, vincristine, and prednisone, with or without rituximab (CHOP ± R). Researchers found:

• One year before treatment, 79% of patients were obese or overweight.

• During the 12 months prior to treatment, 57% of patients lost weight.

• Among patients surviving 24 months after starting treatment, weight increased an average of 2.9 kg above weight at treatment completion.

Citation: O’Brian K, Ganti LS, Riedell P, et al. Short- and long-term weight changes among United States veterans with diffuse large B-cell lymphoma treated with CHOP chemotherapy. [Published online ahead of print July 25, 2015]. Leuk Lymphoma. doi: 10.3109/10428194.2015.1056183.